Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVATE phase 3 study of DNTH103 in adults with chronic inflammatory demyelinating polyneuropathy
2024-517529-26-00Phase 3Authorised
- Sponsor
- Dianthus Therapeutics
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing DNTH103 with Placebo matching DNTH103 (2 arms). Primary endpoint: Time from first dose to relapse as assessed by the adjusted Inflammatory Neuropathy Cause and Treatment score. Planned start Aug 2025; status: authorised.
02
Drugs
claseprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-517529-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517529-26-00.